CN106420891A - Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome - Google Patents
Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome Download PDFInfo
- Publication number
- CN106420891A CN106420891A CN201610839000.XA CN201610839000A CN106420891A CN 106420891 A CN106420891 A CN 106420891A CN 201610839000 A CN201610839000 A CN 201610839000A CN 106420891 A CN106420891 A CN 106420891A
- Authority
- CN
- China
- Prior art keywords
- cortex eucommiae
- folium cortex
- medicine
- flavonoids
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to application of folium cortex eucommiae general flavone in preparation of medicine for treating the perimenopausal syndrome. The purpose of application of the folium cortex eucommiae general flavone serving as a unique active ingredient in preparation of the medicine for treating the perimenopausal syndrome can be effectively achieved. According to the folium cortex eucommiae general flavones, folium cortex eucommiae is crushed into coarse powder, petroleum ether is firstly used for reflux extraction, degreasing is carried out, petroleum ether is dried in folium cortex eucommiae residues, ethyl alcohol is added for soaking, reflux extraction is carried out, filtering is carried out, ethyl alcohol is subjected to pressure reduction recycling till no alcohol smell exists, distilled water is added for dispersing, and medicine liquid is obtained; the medicine liquid is fed to AB-8 type macroreticular resin, distilled water is firstly used for elution, and water eluant is removed; then ethyl alcohol with the mass concentration being 10% is used for elution, and eluant is removed; ethyl alcohol with the mass concentration being 80% is used for elution, 80% ethyl alcohol eluant is collected, ethyl alcohol is subjected to pressure reduction recycling till no alcohol smell exists, freeze drying is carried out, crushing is carried out, and folium cortex eucommiae general flavone is obtained. The folium cortex eucommiae general flavone is rich in raw material, simple in preparation method, easy to operate and high in production efficiency and is effectively used for preparing the medicine for treating the perimenopausal syndrome, and new application of folium cortex eucommiae is created.
Description
Technical field
The present invention relates to medical, particularly a kind of Flavonoids from Eucommia ulmoides Leaves is in preparation treatment perimenopausal syndrome medicine
Application.
Background technology
Folium cortex eucommiae not only has identical active ingredient and pharmacological action with Bark of Eucommia Ulmoides, and it is more rich to originate, and cost is lower.
There is preferable exploitation prospect, micro-pungent, temperature.Return liver and kidney channel, filling liver kidney；Strengthening the bones and muscles；Hypotensive, for kidney deficiency and liver, head
Dizzy dizzy, soreness of waist and knee joint, muscles and bones impotence, pain in back and loin；Sufficient knees soreness is weak；High blood pressure.
One period before and after perimenopausal syndrome refers to postmenopausal women (starts to menopause 12 months from one's mid-40s
Interior period), including from the endocrine relevant with menopause close to menopause appearance, biology and Clinical symptoms to last 1 time month
Through after 1 year, that is, the sign of ovarian failure, be continued until 1 year after last 1 menstruation, be normal physiological change
Period.But easily there is discomfort in climacteric, clinical manifestation is change in menstrual cycle characteristics, the blood vessel such as flush, a burst of heating, perspiration relaxes
Open symptom.Emotional instability, exciting irritability, depressed many tired, failure of memory, ability to work declines etc., wrinkle of skin gradually increases
Many, some appearance itch, hair start to bleach and come off.Belly and bung fat increase, and easily get fat, and blood pressure easily fluctuates, and often go out
Existing hypertension, precordial fullness pain discomfort, palpitaition, shortness of breath, artery sclerosis incidence increases, and Incidence of CHD also rises, sclerotin
Loose, above-mentioned symptom is referred to as perimenopausal syndrome.
Though the existing multi-medicament having treatment perimenopausal syndrome, so far there are no the folium cortex eucommiae extracting from folium cortex eucommiae
Application in preparation treatment perimenopausal syndrome medicine for the general flavone.
Content of the invention
For above-mentioned situation, for overcoming the defect of prior art, the purpose of the present invention is exactly to provide a kind of folium cortex eucommiae always yellow
Ketone preparation treatment perimenopausal syndrome medicine in application, can effectively solving Flavonoids from Eucommia ulmoides Leaves as sole active agent
Application problem in preparing perimenopausal syndrome medicine.
The technical scheme that the present invention solves is that Flavonoids from Eucommia ulmoides Leaves encloses in preparation treatment as sole active position (composition)
Application in climacteric syndrome medicine, this Flavonoids from Eucommia ulmoides Leaves is that Eucommia Leaf Powder is broken into meal, is first carried with petroleum ether backflow
Take, degreasing, the folium cortex eucommiae dregs of a decoction volatilize petroleum ether, plus ethanol soak, refluxing extraction, filter, decompression recycling ethanol to no alcohol taste, plus
Distilled water disperses, and obtains liquid；AB-8 type macroporous absorbent resin on liquid, first with distillation water elution, discards water elution；Use matter again
Amount concentration 10% ethanol elution, discards eluent；Use mass concentration 80% ethanol elution again, collect 80% ethanol eluate, subtract
Push back receipts ethanol to no alcohol taste, freeze-drying, pulverize, obtain Flavonoids from Eucommia ulmoides Leaves.
The Flavonoids from Eucommia ulmoides Leaves of present invention preparation is as sole active agent in preparation treatment perimenopausal syndrome medicine
In application, abundant raw material, preparation method is simple, easy to operate, and production efficiency is high, comprehensive effective for preparation treatment climacteric
The medicine levied, has opened up the new application of folium cortex eucommiae, is the innovation on Chinese medicine, has significant economic and social benefit.
Specific embodiment
Below in conjunction with concrete condition, the specific embodiment of the present invention is elaborated.
In being embodied as, Flavonoids from Eucommia ulmoides Leaves encloses menopause as sole active position (composition) in preparation treatment to the present invention
Application in phase syndrome medicine, this Flavonoids from Eucommia ulmoides Leaves is the meal that Eucommia Leaf Powder was broken into 20-30 mesh sieve, first overstriking powder
Petroleum ether refluxing extraction 1h of 10 times of weight, degreasing, the folium cortex eucommiae dregs of a decoction volatilize petroleum ether, overstriking powder 10 times of weight, mass concentrations
80% ethanol soaks 0.5h, refluxing extraction 1h, filters, obtains first time filtrate；The dregs of a decoction 10 times of weight, mass concentrations of overstriking powder again
80% alcohol reflux extracts 1h, filters, and obtains second filtrate, merges filtrate twice, and decompression recycling ethanol is to no alcohol taste, plus distillation
Moisture is dissipated to and is equivalent to 0.3g/ml containing crude drug amount, obtains liquid；AB-8 type macroporous absorbent resin on liquid, is first steamed with 2 times of column volumes
Distilled water elutes, and discards water elution；Again with mass concentration 10% ethanol elution of 4 times of column volumes, discard eluent；Again with 6 times
Mass concentration 80% ethanol elution of column volume, collects 80% ethanol eluate, decompression recycling ethanol to no alcohol taste, freezing is dry
Dry, pulverize, obtain Flavonoids from Eucommia ulmoides Leaves.
Through test, Flavonoids from Eucommia ulmoides Leaves, as sole active agent, can be effectively used for preparation treatment climacteric to the present invention
The medicine of syndrome, relevant testing data is as follows：
1 experiment material
1.1 animal used as test
KM mouse, SPF level；Sex：Female；Body weight：23-25g, provides unit：Lukang Medical Co., Ltd., Shandong；
Animal quality certification number：37005400000020；Experimental Ethical is numbered：DWLL16020050；In Henan College Of Traditional Chinese Medicine zoopery
Heart credit number：SYXK (Henan) 2015-0005.
1.2 Experimental agents
Flavonoids from Eucommia ulmoides Leaves of the present invention, content>55%.Geng Nian An Capsules are (glutinous rehmannia, prepared rhizome of rehmannia, rhizoma alismatis, the tuber of dwarf lilyturf, radix scrophulariae, male
The root bark of tree peony, Poria cocos, mother-of-pearl, thizoma curculiginis, the fruit of Chinese magnoliavine, magnetite, the vine of multiflower knotweed, yncaria stem with hooks, light wheat, prepared fleece flower root.Auxiliary material is Capsules.
Proterties：This product is capsule, and content is the particle of pitchy；Gas micro-perfume, taste is micro- sweet then bitter.Indication：Nourishing and suppressing Yang,
Relieving restlessness is calmed the nerves.For climacteric hectic fever sweating, dizziness and tinnitus, irritated insomnia.Specification：Every dress 0.3g；Usage and dosage：It is oral,
One time 3,3 times a day, Shanxi Yellow River Traditional Chinese Medicine Co., Ltd. produce.
1.3 experiment reagent
Chloraldurate, Tianjin Ke Miou chemicals development centre；Sodium carboxymethylcellulose, examination is learned in perseverance Xinghua, Tianjin
Agent Manufacturing Co., Ltd；Benzylpenicillin sodium for injection, Huabei Pharmaceutic Co., Ltd；0.9% sodium chloride injection, Henan Cologne
Limited point of department of medicine company；Formalin (analysis is pure), Chemical Co., Ltd. in pairs of Yantai City；Alcohol：The big disinfectant preparation in Xinxiang City three
Co., Ltd；Mouse E2ELISA detection kit, R＆D company；Mouse T ELISA detection kit, R＆D company；Mouse LH
ELISA detection kit, R＆D company；Mouse FSH ELISA detection kit, R＆D company；Mouse IL-2ELISA detection examination
Agent box, R＆D company.
1.4 laboratory apparatus
Electronic scale, Shanghai Minqiao Medical Apparatus and Instruments Co., Ltd., model JY601；Electronic analytical balance, Ao Haosi (Shanghai) is public
Department, model AR1140/C；High speed tabletop centrifuge, Anting Scientific Instrument Factory, Shanghai, model TGL-168；Electric-heated thermostatic water bath,
Shanghai Yiheng Scientific Instruments Co., Ltd, model HWS12；High speed freezing centrifuge, good point in Keda Innovation Co., Ltd
Company, model KDC-160HR；Adjustable pipette, Shanghai Lei Bo Analytical Instrument Co., Ltd；Mouse autonomic activities tester,
Chengdu TME Technology Co., Ltd., model ZZ-6；Mouse keeps away dark instrument, Chengdu TME Technology Co., Ltd., model：BA-200；Enzyme
Mark instrument, BIO-RAD company of the U.S., model 680；Electric microscope, Japanese OLYMPUS company, model BX61.
2 experimental techniques
2.1 modelings and administration
Modeling method：Take body weight 23～25g female KM mouse 84, select 10 at random and be only used as blank, do sham-operation
Process, remaining mouse makes climacteric model.After mouse weights pneumoretroperitoneum injects 10% chloraldurate (0.03ml/10g) anesthesia
Abdomen position is fixed, then from mouse back most end rib, in midaxillary line and about 1cm infall cropping outside backbone, after sterilization
Cut skin and dorsal muscles about 0.5～1cm, the shinny cellulite of a visible milky in the otch visual field, ovary embeds wherein.With
Pincet is gently clamped outside cellulite pull-out otch, fractionation of fatty group, you can see one thin-line-shaped be in irregularly yellowish red color
Ovary.First by fallopian tubal under ovary (including fat) fine rule ligation during clip, then extract ovary, cornua uteri is put by postoperative taking advantage of a situation
Return in abdominal cavity, suture muscle and skin, extract bilateral ovaries with method.Careful postoperative is raised, intramuscular injection penicillin 250,000 u/kg
(every 0.02mL) is in case infect, continuous 3d, once a day.Start by only carrying out mouse vagina plate coating checking, daily after operation 5d
1 time, continuous 5d, to determine whether ovary is excised completely.Smear assumes the mouse emotionally reacting and is discarded, and selects 60 castrations
Completely mouse is uniformly divided into 6 groups at random for experiment, respectively model group, Geng Nian An Capsules group, soybean isoflavone soft capsule
Group, large, medium and small dosage Flavonoids from Eucommia ulmoides Leaves group.
Make up a prescription：0.5%CMC compound method：Weigh sodium carboxymethylcellulose 4g, be made into 800ml with distilled water.
Large, medium and small dosage Flavonoids from Eucommia ulmoides Leaves group dosage is respectively 400mg kg-1、200mg·kg-1、
100mg·kg-1(administered volume 0.1ml/10g).
Geng Nian An Capsules (675mg kg-1, concentration 67.5mg mL-1, be equivalent to 15 times of quantity)；Configuration side
Method：Take Geng Nian An Capsules 9, be first suspended in a small amount of 0.5%CMC solution, then constant volume, to 40ml, mixes again, as required
Geng Nian An Capsules suspension.
Isoflavones ties up E soft capsule (250mg kg-1, concentration 25mg mL-1, be equivalent to 15 times of quantity)；
Collocation method：Take soybean isoflavones capsules 2, be first suspended in a small amount of 0.5%CMC solution, then constant volume, to 40ml, mixes again
Even, as required isoflavones suspension.
Storage method：Refrigeration, used time water proof warms
Medication：Each group animal gives relative medicine on the 10th day in Post operation.Geng Nian An Capsules group gavages climacteric-syndrome-relieving tablet glue
Capsule suspension 675mg kg-1, soybean isoflavone soft capsule group gavages soybean isoflavone soft capsule suspension 250mg kg-1,
Group gavages large, medium and small dosage Flavonoids from Eucommia ulmoides Leaves 400mg kg to large, medium and small dosage Flavonoids from Eucommia ulmoides Leaves group respectively-1、
200mg·kg-1、100mg·kg-1.Blank group and model group gavage same volume distilled water respectively, daily gastric infusion 1 time, even
Continuous administration 21d.
2.2 observation items and detection method
Each group mouse measures autonomic activities number of times in 5min when being administered 18d, measures mouse first when being administered 19～20d
Enter the number of times being shocked by electricity in the incubation period in darkroom and 5min interior entrance darkroom.After last dose, 2h (water 12h is can't help in fasting), little
Mouse is plucked eyeball and takes blood after weighing, separate serum, measures E in serum2, the content of T, LH, FSH, IL-2；Then take off cervical vertebra execution little
Mouse, dissects mouse, extracts thymus gland, spleen, uterine tissue, weighs its weight in wet base and calculates organ index (organ index=internal organs are wet
Weight mg/ Mouse Weight g), then takes brain；Thymus gland, spleen, uterus, brain tissue are fixed in 10% formalin, paraffin bag
Bury, section, HE dyes, the histomorphological changes of light Microscopic observation each group.
2.2.1 autonomic activities number of times is tested
Each group mouse is put in autonomic activities instrument, first adapts to environment 1min, then measure autonomic activities number of times in 5min.
2.2.2 darkness avoidance test test
Each group mouse tail is put in determination box against the osculum entering darkroom, is trained, redeterminates little after 24h
Mouse first enters into the number of times being shocked by electricity in the incubation period in darkroom and 5min interior entrance darkroom.
2.2.3 kit measurement method
Mouse E2 (E2), testosterone (T), lutropin (LH), follicle-stimulating hormone (FSH), interleukin 2 (IL-2)
ELISA detection kit assay method refers to specification.
2.3 statistical procedures methods
Data analysis carries out the statistical procedures of data information, measurement data average with SPSS17.0 medical statistics bag
± standard deviationRepresent, compare between each group and adopt one-way analysis of variance, the neat person of variance test uses LSD method, heterogeneity of variance
Person is checked with Games-Howell method, and ranked data adopt Ridit to check.
Result
1. the impact of pair climacteric model mice autonomic activities
The impact to climacteric model mice autonomic activities for the Flavonoids from Eucommia ulmoides Leaves, the results are shown in Table 1.
The impact to climacteric model mice autonomic activities for table 1 Flavonoids from Eucommia ulmoides Leaves
Note：Compare with model group, * P<0.05, * * P<0.01
As seen from Table 1, with blank group ratio, the activity of model group mouse, number of times of standing all substantially reduce (P<0.01), instead
Reflect climacteric model mice the curious degree of fresh ambient is reduced.With model group ratio, soybean isoflavone soft capsule group, more
Number of activities (the P that year pacifies Capsules group, big, middle dosage Flavonoids from Eucommia ulmoides Leaves group is all remarkably improved mouse<0.01).
2. affected to climacteric model mice darkness avoidance test incubation period with by number of shocks
Flavonoids from Eucommia ulmoides Leaves is affected to climacteric model mice darkroom incubation period with by number of shocks, the results are shown in Table 2
Table 2 Flavonoids from Eucommia ulmoides Leaves is affected to climacteric model mice darkroom incubation period with by number of shocks
Note：Compare with model group, * P<0.05, * * P<0.01
As shown in Table 2, with blank group ratio, model group mouse dramatically increased (P by number of shocks<0.01), reflect and enclose
Climacteric model mice memory reduces.With model group ratio, soybean isoflavone soft capsule group, Geng Nian An Capsules group, large, medium and small
Dosage Flavonoids from Eucommia ulmoides Leaves group all can significantly extend darkroom incubation period, reduce mouse and be subject to number of shocks (P<0.01).
3. the impact of pair climacteric model mice organ index
Flavonoids from Eucommia ulmoides Leaves to climacteric model mice thymus gland, spleen, uterus index impact, the results are shown in Table 3.Table 3
Flavonoids from Eucommia ulmoides Leaves to climacteric model mice thymus gland, spleen, uterus index impact
Note：*P<0.05, * * P<0.01, represent and compare with model group
As shown in Table 3, with blank group ratio, the uterus index of model group mouse significantly reduces (P<0.01), illustrate to extract ovum
Nest leads to climacteric model mice metratrophia.With model group ratio, soybean isoflavone soft capsule group, Geng Nian An Capsules group, in
Dosage Flavonoids from Eucommia ulmoides Leaves group is all remarkably improved thymus gland, spleen, uterus index (P<0.01).
4. the impact of pair climacteric model mice Serum Sex Hormones content
Flavonoids from Eucommia ulmoides Leaves is to E in climacteric model mice serum2, the impact of T content, the results are shown in Table 4；Folium cortex eucommiae is total
The impact to FSH, LH content in climacteric model mice serum for the flavones, the results are shown in Table 5.
Table 4 Flavonoids from Eucommia ulmoides Leaves is to E in climacteric model mice serum2, the impact of T content
Note：*P<0.05, * * P<0.01, represent and compare with model group
The impact to FSH, LH content in climacteric model mice serum for table 5 Flavonoids from Eucommia ulmoides Leaves
Note：*P<0.05, * * P<0.01, represent and compare with model group
Be can be seen that and blank group ratio by table 4, table 5, in model group mice serum, E2, T level is remarkably decreased (P<
0.01), LH, FSH level all significantly raises (P<0.01), illustrate that the sex hormone level in mice serum is disorderly, climacteric is little
Mouse model replicates successfully.With model group ratio, heavy dose of Flavonoids from Eucommia ulmoides Leaves group all can significantly increasing serum E2, T level (P<
0.01) hence it is evident that reducing the LH, FSH level (P raising<0.05).
5. the impact of pair climacteric model mice Serum IL-2
The impact to climacteric model mice Serum IL-2 for the Flavonoids from Eucommia ulmoides Leaves, the results are shown in Table 6.
The impact to climacteric model mice Serum IL-2 for table 6 Flavonoids from Eucommia ulmoides Leaves
Note:*P<0.05, * * P<0.01, represent and compare with model group
As shown in Table 6, with blank group ratio, in model group mice serum, IL-2 level is remarkably decreased (P<0.01), illustrated
Caused by full excision ovary, climacteric mouse model immunity of organisms decreases.With model group ratio, each administration group all can be notable
Increasing serum IL-2 level (P<0.01).
6. the impact of pair climacteric model mice organ-tissue form
Flavonoids from Eucommia ulmoides Leaves model mice uterus, thymus gland, spleen, the pathologic examination of hypophysis, using micrometer, survey
Surely test the thickness of every endometrium of mouse of each group.The results are shown in Table 7；Using micrometer, to experiment every mouse thymus of each group
Cortex thickness and the narrowest place measure its thickness and try to achieve mean；Then record, with the baseline of micrometer, the chest gland skin being pressed on baseline
The lymphocyte number at matter thickness and the narrowest place tries to achieve mean, the results are shown in Table 8；Fall on splenic corpuscle using the baseline of micrometer,
Measure the splenic corpuscle thickness size of both sides respectively centered on central artery, seek mean；Calculate both sides on baseline simultaneously
The number of lymphocyte number, seeks mean；Using adenohypophyseal quantity try to achieve mean value on micrometer measurement diagonal.
The impact to climacteric model mice endometrium thickness for table 7 Flavonoids from Eucommia ulmoides Leaves
Note:*P<0.05, * * P<0.01, represent and compare with model group
As shown in Table 7, with blank group ratio, model group endometrium of mouse thickness is remarkably decreased (P<0.01), illustrate completely
Extract the notable metratrophia of climacteric mouse model caused by ovary.With model group ratio, soybean isoflavone soft capsule group, climacteric-syndrome-relieving tablet
Capsules group, heavy dose of Flavonoids from Eucommia ulmoides Leaves Capsules group all can significantly raise the thickness (P of endometrium<0.01).
6.2 pairs of climacteric model mice thymus gland, the impacts of spleen tissue form
The impact to climacteric model mice thymus gland for table 8 Flavonoids from Eucommia ulmoides Leaves
Note：*P<0.05, * * P<0.01, represent and compare with model group
As known from Table 8, with blank group ratio, model group Mouse Thymic Cortex thickness, splenic corpuscle volume substantially reduce (P<
0.01), illustrate that mouse makes thymus gland, spleen volume atrophy after climacteric model.With model group ratio, soybean isoflavones capsules, more
Year peace capsule, big, middle dosage Flavonoids from Eucommia ulmoides Leaves group can significantly thicken thymic cortex and splenic corpuscle volume (P<0.01).
The impact of 6.3 pairs of mouse climacteric model pituitary tissue forms
The impact to climacteric model mice adenohypophysis quantity for table 9 Flavonoids from Eucommia ulmoides Leaves
Note:*P<0.05,**P<0.01, represent and compare with model group
As known from Table 9, with blank group ratio, the adenohypophyseal quantity of model group substantially reduces (P<0.01), illustrate that mouse is made to enclose
After climacteric model, secretion promotees the cell source minimizing of sex hormone.With model group ratio, large, medium and small dosage Flavonoids from Eucommia ulmoides Leaves group can
Dramatically increase adenohypophyseal quantity volume (P<0.01).
This product should be had to prepare medicine (capsule) for treating perimenopausal syndrome, and through 88 perimenopausal syndromes
Patient clinical is applied, and achieves significant therapeutic effect.Patient daily 3 times, 2 every time, every contains Flavonoids from Eucommia ulmoides Leaves
0.5g, serve on 60 days, and in addition to 2 people, clinical symptom disappearance or clinical symptoms have clear improvement or improver 86 people, efficient up to
97.7%, getting well of effect was not expected, is the innovation on treatment perimenopausal syndrome medicine, has opened up the new of folium cortex eucommiae
Purposes, economic and social benefit is notable.
Claims (1)
1. a kind of Flavonoids from Eucommia ulmoides Leaves application in preparation treatment perimenopausal syndrome medicine as sole active position, should
Flavonoids from Eucommia ulmoides Leaves is the meal that Eucommia Leaf Powder was broken into 20-30 mesh sieve, and the petroleum ether backflow of first 10 times of weight of overstriking powder carries
Take 1h, degreasing, the folium cortex eucommiae dregs of a decoction volatilize petroleum ether, 10 times of weight of overstriking powder, mass concentration 80% ethanol soak 0.5h, and backflow carries
Take 1h, filter, obtain first time filtrate；10 times of weight of overstriking powder, mass concentration 80% alcohol reflux extract 1h to the dregs of a decoction again, filter, obtain
Second filtrate, merges filtrate twice, decompression recycling ethanol is to no alcohol taste, plus distilled water is dispersed to and is equivalent to containing crude drug amount
0.3g/ml, obtains liquid；AB-8 type macroporous absorbent resin on liquid, first distills water elution with 2 times of column volumes, discards water elution；
Again with mass concentration 10% ethanol elution of 4 times of column volumes, discard eluent；Again with mass concentration 80% ethanol of 6 times of column volumes
Wash-out, collects 80% ethanol eluate, decompression recycling ethanol to no alcohol taste, freeze-drying, pulverizes, obtain Flavonoids from Eucommia ulmoides Leaves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610839000.XA CN106420891A (en) | 2016-09-21 | 2016-09-21 | Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610839000.XA CN106420891A (en) | 2016-09-21 | 2016-09-21 | Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420891A true CN106420891A (en) | 2017-02-22 |
Family
ID=58166390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610839000.XA Pending CN106420891A (en) | 2016-09-21 | 2016-09-21 | Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420891A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334795A (en) * | 2017-08-12 | 2017-11-10 | 河南中医药大学 | Application of the Chinese trumpet creeper general flavone as sole active agent in preparing treatment Streptozotocin and causing diabetes medicament |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104083473A (en) * | 2014-07-24 | 2014-10-08 | 河南中医学院 | Application of raspberry extract in preparation of drug for treating perimenopausal syndrome |
-
2016
- 2016-09-21 CN CN201610839000.XA patent/CN106420891A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104083473A (en) * | 2014-07-24 | 2014-10-08 | 河南中医学院 | Application of raspberry extract in preparation of drug for treating perimenopausal syndrome |
Non-Patent Citations (3)
| Title |
|---|
| 和承尧编著: "《高原植物资源开发利用研究》", 31 May 2008, 云南科技出版社 * |
| 魏珍珍等: ""补肾阳中药治疗围绝经期综合征特点分析"", 《中医学报》 * |
| 黄友谊、杨坚编著: "《中国特种茶加工》", 31 July 2004, 中国农业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334795A (en) * | 2017-08-12 | 2017-11-10 | 河南中医药大学 | Application of the Chinese trumpet creeper general flavone as sole active agent in preparing treatment Streptozotocin and causing diabetes medicament |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100402081C (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN102988703B (en) | Traditional Chinese medicine preparation for treating kidney-yang deficiency and preparation method thereof | |
| CN104083473A (en) | Application of raspberry extract in preparation of drug for treating perimenopausal syndrome | |
| CN103169881A (en) | Chinese medicament health product for supplementing female hormone for women during menopause and preparation method thereof | |
| CN1275639C (en) | Medicine for treating women's habitual abortion and threatened abortion | |
| CN101269170B (en) | Medicament for treating climacteric syndrome and preparation method thereof | |
| CN106236799A (en) | The application in preparation treatment perimenopausal syndrome medicine of the Fructus Cnidii total flavones | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN103272119A (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN106390021A (en) | Pharmaceutical composition for preventing and treating uterine fibroid and ovarian cyst as well as preparation method, dosage form and application of pharmaceutical composition | |
| CN106309543A (en) | Application of psoralen total flavonoid in preparation of medicaments for treating perimenopausal syndromes | |
| CN106420891A (en) | Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome | |
| CN102048913B (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof | |
| CN104189349A (en) | Traditional Chinese medicine composition for treating oligomenorrhea | |
| CN106138955A (en) | The application in exhausted premenstrual syndrome medicine is treated in preparation of the Fructus Alpiniae Oxyphyllae total flavones | |
| CN106420945A (en) | Application of cistanche phenylethanoid glycoside in preparation of medicine for treating perimenopausal syndrome | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN104873714A (en) | Menopausal woman syndrome treatment kidney-tonifying and wind evil dispelling climacteric prescription preparation method | |
| CN103919961B (en) | Middle and old age kidney-jing deficiency and kidney yang deficiency treatment traditional Chinese medicine preparation and preparation method thereof | |
| CN102366621A (en) | Plant estrogenic effect of acanthopanax biochemical traditional Chinese medicine compound extract and its application | |
| CN104940513A (en) | Pharmaceutical composition for treating menopause syndrome | |
| CN106266476B (en) | Green onion seed general flavone treats the application in premenopausal syndrome drug in preparation | |
| CN105250754B (en) | It is a kind of alleviate menopause symptom Chinese medicine composition and its application | |
| CN109010418A (en) | A kind of method and application for extracting fenugreek extract from faenum graecum | |
| CN106075007A (en) | The application in preparation treatment study on perimenopausal depressive disorder medicine of the leek seed total flavone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |